Live presentation and Q&A; hosted by Jefferies Equity Research on Tuesday, October 26, 2021 at 11 a.m.ET

Guest speakers include Jason Luke, MD, FACP and Art Krieg, MD

CAMBRIDGE, Mass., October 20, 2021 (GLOBE NEWSWIRE) – Checkmate Pharmaceuticals, Inc. (Nasdaq: CMPI) (“Checkmate”), a clinical-stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system Cancer Control System, today announced a live webcast on Innate Immune Modulators and Vidutolimod (CMP-001) hosted by Jefferies on Tuesday, October 26 from 11:00 a.m. to 12:00 p.m. ET.

The webcast will be moderated by Maury Raycroft, Ph.D. and feature Jason Luke, MD, FACP and Art Krieg, MD in a scientific discussion on the role of innate immune modulators in cancer treatment. Dr Luke will review the different approaches to modulate innate immunity for cancer treatment and the challenges faced by the field. Dr Krieg will discuss the unique modality and mechanism of action of vidutolimod, an advanced generation biological agonist of the Toll-like 9 receptor (TLR9), which is undergoing advanced clinical trials for patients with melanoma and proof of concept clinical trials. for patients with head and neck cancer, cutaneous squamous cell carcinoma and Merkel cell carcinoma.

Dr Luke is an internationally renowned clinical and translational researcher in the field of melanoma and early drug development, particularly in immuno-oncology. Dr. Krieg is the Founder and Scientific Director of Checkmate Pharmaceuticals, Inc. He has published over 250 scientific papers and is the inventor of over 50 issued US patents covering oligonucleotide technologies.

The webcast is accessible under “Events and Presentations” in the Investors section of the Checkmate website. An archived copy of the webcast will be available on Checkmate’s website for approximately 90 days after the event.

About Checkmate Pharmaceuticals

Checkmate Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary technology to harness the power of the immune system to fight cancer. Checkmate Pharmaceuticals’ product candidate, vidutolimod (CMP-001), is an advanced generation Toll-like 9 (TLR9) agonist, delivered as a biological viral particle using CpG-A oligodeoxynucleotide as a key component, designed to trigger the body’s innate immune system to attack tumors in combination with other therapies. Information about Checkmate Pharmaceuticals is available at www.checkmatepharma.com.

Availability of other information on Checkmate Pharmaceuticals

Investors and others should note that we communicate with our investors and the public using our website (www.checkmatepharma.com), our investor relations website (ir.checkmatepharma.com) and on social media (Twitter and LinkedIn), including but not limited to: investor presentations and investor information sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Checkmate Pharmaceuticals publishes on these channels and websites could be considered important information. Therefore, we encourage investors, the media and others interested in us to regularly review the information posted on these channels, including the Investor Relations website. This channel list may be updated from time to time on our Investor Relations website and may include additional social media channels. The content of our website or these channels, or any other website accessible from our website or these channels, will not be deemed to be incorporated by reference in a filing under the Securities Act of 1933.

Forward-looking statements

Various statements contained in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including words such as, but not limited to, “anticipate”, “believe” , “Could”, “could”, “expect”, “estimate”, “conceive”, “objective”, “intend”, “can”, “could”, “could”, “objective” , “Plan”, “predict”, “plan”, “target”, “” likely “,” should “,” will “and” would “, or the negative of these terms and expressions or similar words, identify forward-looking statements . Forward-looking statements are based on current expectations that involve risks, changes in circumstances, assumptions and uncertainties. These statements include those regarding vidutolimod (CMP-001), including its development and therapeutic potential and advancement of our clinical and preclinical pipeline; expectations regarding results and data analysis; and expectations regarding the timing, initiation, implementation and success of its planned and ongoing clinical trials for vidutolimod and the related benefits and implications of current and future partnerships and / or collaborations; and expectations regarding the use of capital, expenses and other financial results of the Company. Forward-looking statements should not be interpreted as a guarantee of future performance or results and may not be precise indications of when such performance or results will be achieved. These forward-looking statements are subject to risks and uncertainties, including those relating to the development of our product candidate, including any delay in our ongoing or planned preclinical or clinical trials, clinical trial results, including the fact that positive trial results may not necessarily be predictive of future or ongoing clinical trial results, the impact of the ongoing COVID-19 pandemic on our business, operations, clinical supply and our plans, the risks inherent in the drug development process, the risks relating to the accuracy of our expenditure estimates and development schedule, our capital requirements and the need for additional financing, and in obtaining, maintaining and the protection of our intellectual property. These and other risks are discussed in the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” of our Quarterly Report on Form 10-Q for the three months ended 30 June 2021 and in our Annual Report on Form 10-K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission, available on the Securities and Exchange Commission website at address www.sec.gov, as well as discussions of potential risks, uncertainties and other important factors in our subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of publication, and Checkmate does not undertake to update such information, except as required by law.